NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$0.49 USD
-0.01 (-1.52%)
Updated Aug 30, 2024 03:58 PM ET
After-Market: $0.49 0.00 (0.68%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for NovaBay Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3 | 5 | 8 | 12 | 7 |
Receivables | 1 | 2 | 2 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 3 | 3 | 1 | 0 |
Other Current Assets | 0 | 1 | 1 | 1 | 1 |
Total Current Assets | 7 | 11 | 13 | 14 | 9 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 3 | 10 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 0 |
Total Assets | 9 | 16 | 24 | 15 | 11 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 1 | 0 | 0 | 0 | 3 |
Accounts Payable | 1 | 1 | 1 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 3 | 2 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 4 | 4 | 3 | 3 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 10 | 0 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 6 | 14 | 3 | 10 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 2 | 3 | 1 | 0 | 0 |
Common Stock (Par) | 0 | 1 | 0 | 0 | 0 |
Capital Surplus | 176 | 165 | 151 | 148 | 126 |
Retained Earnings | -175 | -158 | -142 | -136 | -125 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 3 | 11 | 10 | 12 | 1 |
Total Liabilities & Shareholder's Equity | 9 | 16 | 24 | 15 | 11 |
Total Common Equity | 1 | 8 | 9 | 12 | 1 |
Shares Outstanding | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 |
Book Value Per Share | 4.53 | 7.58 | 9.49 | 12.32 | 0.97 |
Fiscal Year End for NovaBay Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 2 | 3 | 3 | 4 |
Receivables | 1 | 1 | 1 | 1 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 3 | 3 | 4 |
Other Current Assets | 0 | 0 | 0 | 0 | 1 |
Total Current Assets | 2 | 4 | 7 | 8 | 11 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 3 | 3 |
Deposits & Other Assets | 0 | 0 | 1 | 1 | 1 |
Total Assets | 4 | 5 | 9 | 13 | 16 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 1 | 1 | 1 | 1 | 1 |
Accounts Payable | 1 | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 2 | 2 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 4 | 4 | 4 | 5 | 6 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5 | 5 | 6 | 6 | 7 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 1 | 2 | 2 | 2 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 1 |
Capital Surplus | 179 | 177 | 176 | 171 | 170 |
Retained Earnings | -180 | -178 | -175 | -166 | -164 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -1 | 0 | 3 | 7 | 9 |
Total Liabilities & Shareholder's Equity | 4 | 5 | 9 | 13 | 16 |
Total Common Equity | -1 | -1 | 1 | 5 | 6 |
Shares Outstanding | 1.30 | 1.00 | 0.30 | 0.10 | 0.10 |
Book Value Per Share | -0.48 | -1.33 | 4.53 | 50.60 | 64.40 |